Suvretta funds boost Veradermics (MANE) position with pre-funded warrants

Rhea-AI Filing Summary

Suvretta Capital–related funds filed Amendment No. 1 to their Schedule 13D on Veradermics, Inc., updating their ownership and warrant holdings. Suvretta Capital Management and Aaron Cowen report beneficial ownership of 4,172,121 shares of common stock, representing 9.9% of the class, including 3,151 shares issuable upon exercise of Pre-Funded Warrants.

Averill Master Fund, Ltd. reports 3,650,103 shares, or 8.7% of the class, and Averill Madison Master Fund, Ltd. reports 522,018 shares, or 1.2%. The amendment describes an April 29, 2026 Securities Purchase Agreement under which Averill Master Fund acquired 149,000 Pre-Funded Warrants and Averill Madison Master Fund acquired 151,000, each at $99.99999 per warrant with a $0.00001 exercise price, subject to a Beneficial Ownership Limitation of generally 9.99%, or up to 19.99% upon election.

Key Figures

Suvretta/Cowen beneficial ownership: 4,172,121 shares (9.9%) Averill Master Fund stake: 3,650,103 shares (8.7%) Averill Madison Master Fund stake: 522,018 shares (1.2%) +5 more

8 metrics

Suvretta/Cowen beneficial ownership 4,172,121 shares (9.9%) Veradermics common stock including 3,151 shares issuable on Pre-Funded Warrants

Averill Master Fund stake 3,650,103 shares (8.7%) Includes 1,565 shares issuable on Pre-Funded Warrants

Averill Madison Master Fund stake 522,018 shares (1.2%) Includes 1,586 shares issuable on Pre-Funded Warrants

Private placement warrant totals 300,000 Pre-Funded Warrants 149,000 to Averill Master Fund and 151,000 to Averill Madison Master Fund

Pre-Funded Warrant purchase price $99.99999 per warrant Exercise price $0.00001 per share

Averill Master Fund cash outlay $14,899,998.51 Total purchase price for 149,000 Pre-Funded Warrants

Averill Madison Fund cash outlay $15,099,998.49 Total purchase price for 151,000 Pre-Funded Warrants

Beneficial Ownership Limitation 9.99% or up to 19.99% Maximum post-exercise ownership allowed for warrant holders

Key Terms

Pre-Funded Warrants, Beneficial Ownership Limitation, Securities Purchase Agreement, Schedule 13D, +1 more

5 terms

Pre-Funded Warrants financial

"the Issuer agreed to sell to the Funds in a private placement (the "Private Placement") pre-funded warrants (the "Pre-Funded Warrants")"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

Beneficial Ownership Limitation regulatory

"would beneficially own in excess of 9.99% (or, upon election by such holder, an amount up to 19.99%) ... (the "Beneficial Ownership Limitation")"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

Securities Purchase Agreement financial

"the Issuer entered into a securities purchase agreement (the "Securities Purchase Agreement") with each of the Funds"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

Schedule 13D regulatory

"Neither the filing of this nor any of its contents shall be deemed to constitute an admission that any Reporting Person ... for purposes of Section 13(d)"

A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.

Section 13(d) group regulatory

"together with its affiliates and any members of a Section 13(d) group with such holder"

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Veradermics, Inc

(Name of Issuer)

Common Stock, par value $0.00001

(Title of Class of Securities)

922967104

(CUSIP Number)

Andrew Nathanson
Suvretta Capital Management, LLC, 540 Madison Avenue, 7th Floor
New York, NY, 10022
(212) 702-5205

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/01/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

SUVRETTA CAPITAL MANAGEMENT, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4,172,121.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4,172,121.00

11

Aggregate amount beneficially owned by each reporting person

4,172,121.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.9 %

14

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person:

Note in relation to Items 11 and 13: Includes 4,168,970 shares of Common Stock (as defined below) and 3,151 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (as defined in Item 3 and subject to a beneficial ownership limitation as described therein). Note in relation to Item 13: Based on 41,759,822 shares of Common Stock outstanding as indicated by the Issuer (as defined below) in the final prospectus dated April 29, 2026 and filed by the Issuer on April 30, 2026 (inclusive of 576,568 additional shares of Common Stock purchased by the underwriters in the Issuer's underwritten public offering in May 2026), plus 3,151 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (subject to a beneficial ownership limitation as described therein).

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

Averill Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 3,650,103.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 3,650,103.00

11

Aggregate amount beneficially owned by each reporting person

3,650,103.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.7 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Note in relation to Items 11 and 13: Includes 3,648,538 shares of Common Stock (as defined below) and 1,565 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (as defined in Item 3 and subject to a beneficial ownership limitation as described therein). Note in relation to Item 13: Based on 41,759,822 shares of Common Stock outstanding as indicated by the Issuer (as defined below) in the final prospectus dated April 29, 2026 and filed by the Issuer on April 30, 2026 (inclusive of 576,568 additional shares of Common Stock purchased by the underwriters in the Issuer's underwritten public offering in May 2026), plus 1,565 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (subject to a beneficial ownership limitation as described therein).

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

Averill Madison Master Fund, Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 522,018.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 522,018.00

11

Aggregate amount beneficially owned by each reporting person

522,018.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

1.2 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

Note in relation to Items 11 and 13: Includes 520,432 shares of Common Stock (as defined below) and 1,586 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (as defined in Item 3 and subject to a beneficial ownership limitation as described therein). Note in relation to Item 13: Based on 41,759,822 shares of Common Stock outstanding as indicated by the Issuer (as defined below) in the final prospectus dated April 29, 2026 and filed by the Issuer on April 30, 2026 (inclusive of 576,568 additional shares of Common Stock purchased by the underwriters in the Issuer's underwritten public offering in May 2026), plus 1,586 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (subject to a beneficial ownership limitation as described therein).

SCHEDULE 13D

CUSIP Number(s): 922967104

1

Name of reporting person

Aaron Cowen

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 4,172,121.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 4,172,121.00

11

Aggregate amount beneficially owned by each reporting person

4,172,121.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.9 %

14

Type of Reporting Person (See Instructions)

IN, HC

Comment for Type of Reporting Person:

Note in relation to Items 11 and 13: Includes 4,168,970 shares of Common Stock (as defined below) and 3,151 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (as defined in Item 3 and subject to a beneficial ownership limitation as described therein). Note in relation to Item 13: Based on 41,759,822 shares of Common Stock outstanding as indicated by the Issuer (as defined below) in the final prospectus dated April 29, 2026 and filed by the Issuer on April 30, 2026 (inclusive of 576,568 additional shares of Common Stock purchased by the underwriters in the Issuer's underwritten public offering in May 2026), plus 3,151 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (subject to a beneficial ownership limitation as described therein).

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.00001
(b)	Name of Issuer: Veradermics, Inc
(c)	Address of Issuer's Principal Executive Offices: 470 James Street, New Haven, CONNECTICUT , 06513.
Item 1 Comment: This Amendment No. 1 (this "Amendment") amends and supplements the statement on Schedule 13D filed on February 11, 2026 (the "Original Schedule 13D" and, as amended and supplemented by this amendment referred to herein as the "Schedule 13D"), related to Common Stock of the Issuer. Capitalized terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.
Item 3.	Source and Amount of Funds or Other Consideration
	The information contained in Item 3 of the Original Schedule 13D is hereby amended and supplemented by adding the text set forth below after the last paragraph: On April 29, 2026, the Issuer entered into a securities purchase agreement (the "Securities Purchase Agreement") with each of the Funds pursuant to which the Issuer agreed to sell to the Funds in a private placement (the "Private Placement") pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 300,000 shares of Common Stock at a purchase price of $99.99999 per Pre-Funded Warrant (and with an exercise price of $0.00001 per warrant). Pursuant to the Private Placement, at the closing on May 1, 2026, (i) Averill Master Fund acquired 149,000 Pre-Funded Warrants, at a per warrant price of $99.99999 and a total purchase price of $14,899,998.51, and (ii) Averill Madison Master Fund acquired 151,000 Pre-Funded Warrants, at a per warrant price of $99.99999 and a total purchase price of $15,099,998.49. The Pre-Funded Warrants issued in the Private Placement provide that the holder of the Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if such holder, together with its affiliates and any members of a Section 13(d) group with such holder, would beneficially own in excess of 9.99% (or, upon election by such holder, an amount up to 19.99%) of the number of shares of Common Stock that would be issued and outstanding following such exercise (the "Beneficial Ownership Limitation"). As a result of this restriction, only a portion of the Pre-Funded Warrants acquired by the Funds, as described on the cover pages to this Schedule 13D, are exercisable. In addition, the number of shares of Common Stock that may be issued upon exercise of the Pre-Funded Warrants by the Funds may change depending upon changes in the outstanding shares of Common Stock. The total amount of funds used by the Funds to purchase the securities of the Issuer described in this Item 3 was furnished from the working capital of the Funds.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in Item 5 of the Original Schedule 13D is hereby amended and restated to read as follows: (a) and (b) The information contained on the cover pages to this Amendment is incorporated by reference into this Item 5. Mr. Cowen is the control person and managing member of Suvretta Capital and may be deemed to control the other Reporting Persons. Mr. Cowen disclaims beneficial ownership of all shares of Common Stock held by the Funds, other than, to the extent of any pecuniary interest therein. Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any Reporting Person or any of its affiliates is the beneficial owner of any shares of Common Stock for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
(c)	The information disclosed in Items 3 and 6 of this Schedule 13D is incorporated by reference into this Item 5. Except as disclosed in Items 3 and 6 of this Schedule 13D, the Reporting Persons and, to their knowledge, the Scheduled Persons have not effected any transactions in Common Stock during the past sixty days.
(d)	None.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The information contained in Item 6 of the Original Schedule 13D is hereby amended and supplemented by adding the text set forth below after the last paragraph: Securities Purchase Agreement On April 29, 2026, each of the Funds entered into the Securities Purchase Agreement with the Issuer in connection with the Private Placement. Pursuant to the Securities Purchase Agreement, (i) Averill Master Fund acquired 149,000 Pre-Funded Warrants, at a per warrant price of $99.99999, and (ii) Averill Madison Master Fund acquired 151,000 Pre-Funded Warrants, at a per warrant price of $99.99999. Pre-Funded Warrants Each Pre-Funded Warrant has an exercise price of $0.00001 per share. The Pre-Funded Warrants are exercisable at any time after their original issuance and will expire when exercised in full; provided, that the Pre-Funded Warrants cannot be exercised if, after giving effect to such exercise, the holder thereof, together with its affiliates and any members of a Section 13(d) group with such holder, would beneficially own more than 9.99% (or, upon election by such holder, an amount up to 19.99%) of the number of shares of Common Stock that would be issued and outstanding following such exercise. The foregoing descriptions of the material terms of the Securities Purchase Agreement and the form of Pre-Funded Warrant are each qualified in their entirety by reference to those documents, each of which is referenced in Exhibits 4 and 5 hereto, respectively, and is incorporated by reference herein.
Item 7.	Material to be Filed as Exhibits.
	4* Securities Purchase Agreement, dated April 29, 2026, by and among the Issuer and each purchaser identified on the signature pages thereto. 5** Form of Pre-Funded Warrant. *Incorporated by reference from Exhibit 10.1 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 1, 2026. ** Incorporated by reference from Exhibit 4.1 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 1, 2026.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SUVRETTA CAPITAL MANAGEMENT, LLC

Signature:	/s/ Andrew Nathanson
Name/Title:	Andrew Nathanson, General Counsel and Chief Compliance Officer
Date:	05/05/2026

Averill Master Fund, Ltd.

Signature:	/s/ Andrew Nathanson
Name/Title:	Andrew Nathanson, Authorized Signatory
Date:	05/05/2026

Averill Madison Master Fund, Ltd.

Signature:	/s/ Andrew Nathanson
Name/Title:	Andrew Nathanson, Authorized Signatory
Date:	05/05/2026

Aaron Cowen

Signature:	/s/ Aaron Cowen
Name/Title:	Aaron Cowen
Date:	05/05/2026

FAQ

What does Suvretta Capital’s amended Schedule 13D reveal about MANE ownership?

The amendment shows Suvretta Capital Management and Aaron Cowen beneficially owning 4,172,121 Veradermics shares, equal to 9.9% of the common stock, including 3,151 shares issuable from Pre-Funded Warrants, based on 41,759,822 shares outstanding plus the warrant shares.

How many Veradermics (MANE) shares does Averill Master Fund now report?

Averill Master Fund, Ltd. reports beneficial ownership of 3,650,103 Veradermics common shares, representing 8.7% of the class. This includes 3,648,538 shares of common stock and 1,565 shares issuable upon exercise of Pre-Funded Warrants, calculated against the disclosed outstanding share count.

What stake in Veradermics (MANE) is held by Averill Madison Master Fund?

Averill Madison Master Fund, Ltd. reports beneficial ownership of 522,018 Veradermics common shares, or 1.2% of the class. This figure includes 520,432 common shares and 1,586 shares issuable upon exercise of Pre-Funded Warrants, using the same outstanding-share baseline as the other reporting persons.

What are the key terms of the Pre-Funded Warrants related to MANE?

Each Pre-Funded Warrant has a $0.00001 per-share exercise price and was sold at $99.99999 per warrant. They are exercisable after issuance but subject to a Beneficial Ownership Limitation that generally caps post-exercise ownership at 9.99%, or up to 19.99% if the holder elects.

How large was the private placement involving Veradermics (MANE) Pre-Funded Warrants?

The private placement covered up to 300,000 Veradermics shares via Pre-Funded Warrants. At closing, Averill Master Fund acquired 149,000 warrants for $14,899,998.51 and Averill Madison Master Fund acquired 151,000 warrants for $15,099,998.49 under an April 29, 2026 Securities Purchase Agreement.

What Beneficial Ownership Limitation applies to the MANE Pre-Funded Warrants?

The Pre-Funded Warrants restrict exercise if, after exercise, the holder and its affiliates would beneficially own more than 9.99% of Veradermics’ outstanding common stock, unless the holder elects a higher cap of up to 19.99%, limiting how many warrant shares can be exercised at once.